CGRP Plasma Levels Decrease in Classical Trigeminal Neuralgia Patients Treated with Botulinum Toxin Type A: A Pilot...

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Trigeminal neuralgia (TN) is a debilitating neuropathic pain condition.
• Calcitonin gene-related peptide (CGRP) is implicated in pain signaling and inflammation.
• Botulinum toxin type A (BTX-A) is an emerging treatment for TN.

Purpose of the Study:

• To investigate changes in plasma calcitonin gene-related peptide (CGRP) levels in patients with classical trigeminal neuralgia (TN) following treatment with botulinum toxin type A (BTX-A).
• To determine if plasma CGRP concentrations can predict treatment response to BTX-A in TN patients.

Main Methods:

• A cohort of 47 patients with classical TN received BTX-A treatment.
• Plasma CGRP levels were measured using enzyme-linked immunosorbent assay (ELISA) before and after treatment.
• Treatment response was defined as a ≥50% reduction in visual analog scale (VAS) pain scores and episode frequency.

Main Results:

• Plasma CGRP levels significantly decreased after BTX-A treatment in TN patients (P < 0.001).
• Responders showed a significant reduction in CGRP levels post-treatment, while non-responders did not.
• Pre-treatment CGRP levels were not predictive of BTX-A treatment outcomes.

Conclusions:

• CGRP levels are significantly reduced in classical TN patients after BTX-A therapy.
• Plasma CGRP concentration is not a reliable predictor of BTX-A treatment efficacy in TN.
• CGRP likely plays a role in TN pathophysiology, and its inhibition may contribute to BTX-A's analgesic effects.